SuperworthMonte Rosa Therapeutics shares outstanding GLUE
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 101.5M
- On a year earlier
- +23.5%
- more shares
Monte Rosa Therapeutics had 101.5M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 23.5% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 85.5M | +4% |
| FY2024 | 82.1M | +44% |
| FY2023 | 56.9M | +16% |
| FY2022 | 48.9M | +5% |
| FY2021 | 46.5M | +2728% |
| FY2020 | 1.6M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 101.5M | +23% | |
| Q1 FY26 | 99.9M | +20% | |
| Q4 FY25 | 85.5M | +4% | |
| Q3 FY25 | 82.4M | +0% | |
| Q2 FY25 | 82.2M | +15% | |
| Q1 FY25 | 83M | +38% | |
| Q4 FY24 | 82.1M | +44% | |
| Q3 FY24 | 82M | +65% | |
| Q2 FY24 | 71.2M | +44% | |
| Q1 FY24 | 60.2M | +22% | |
| Q4 FY23 | 56.9M | +16% | |
| Q3 FY23 | 49.8M | +7% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Monte Rosa Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.